190 related articles for article (PubMed ID: 36648694)
1. Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference-a Dutch population-based study from 2008 to 2018.
de Maar JS; Luyendijk M; Suelmann BBM; van der Kruijssen DEW; Elias SG; Siesling S; van der Wall E
Breast Cancer Res Treat; 2023 Apr; 198(2):253-264. PubMed ID: 36648694
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
3. Survival of breast cancer patients with synchronous or metachronous central nervous system metastases.
Ho VK; Gijtenbeek JM; Brandsma D; Beerepoot LV; Sonke GS; van der Heiden-van der Loo M
Eur J Cancer; 2015 Nov; 51(17):2508-16. PubMed ID: 26277099
[TBL] [Abstract][Full Text] [Related]
4. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Br J Cancer; 2015 Apr; 112(9):1445-51. PubMed ID: 25880008
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
Gu Y; Wu G; Zou X; Huang P; Yi L
Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
9. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.
Tao L; Chu L; Wang LI; Moy L; Brammer M; Song C; Green M; Kurian AW; Gomez SL; Clarke CA
Cancer Causes Control; 2016 Sep; 27(9):1127-38. PubMed ID: 27496200
[TBL] [Abstract][Full Text] [Related]
10. Survival differences among women with de novo stage IV and relapsed breast cancer.
Dawood S; Broglio K; Ensor J; Hortobagyi GN; Giordano SH
Ann Oncol; 2010 Nov; 21(11):2169-2174. PubMed ID: 20427349
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Value of Additional Primary Tumour Excision Combined with Systemic Therapy Administered in Different Sequences for Patients with de Novo Metastatic Breast Cancer.
Zhu S
Breast J; 2022; 2022():5049445. PubMed ID: 36082023
[TBL] [Abstract][Full Text] [Related]
13. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
Press DJ; Miller ME; Liederbach E; Yao K; Huo D
Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
Yardley DA; Kaufman PA; Brufsky A; Yood MU; Rugo H; Mayer M; Quah C; Yoo B; Tripathy D
Breast Cancer Res Treat; 2014 Jun; 145(3):725-34. PubMed ID: 24706168
[TBL] [Abstract][Full Text] [Related]
15. Regional Lymph Node Involvement Among Patients With De Novo Metastatic Breast Cancer.
Bitencourt A; Rossi Saccarelli C; Morris EA; Flynn J; Zhang Z; Khan A; Gillespie E; Cahlon O; Mueller B; Cuaron JJ; McCormick B; Powell SN; Plitas G; Razavi P; Pinker K; Riedl CC; Sutton EJ; Braunstein LZ
JAMA Netw Open; 2020 Oct; 3(10):e2018790. PubMed ID: 33034638
[TBL] [Abstract][Full Text] [Related]
16. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.
Badwe R; Hawaldar R; Nair N; Kaushik R; Parmar V; Siddique S; Budrukkar A; Mittra I; Gupta S
Lancet Oncol; 2015 Oct; 16(13):1380-8. PubMed ID: 26363985
[TBL] [Abstract][Full Text] [Related]
17. Intervention for Hepatic and Pulmonary Metastases in Breast Cancer Patients: Prospective, Multi-institutional Registry Study-IMET, Protocol MF 14-02.
Soran A; Ozbas S; Ozcinar B; Isik A; Dogan L; Senol K; Dag A; Karanlik H; Aytac O; Karadeniz Cakmak G; Dalci K; Dogan M; Sezer YA; Gokgoz S; Ozyar E; Sezgin E;
Ann Surg Oncol; 2022 Oct; 29(10):6327-6336. PubMed ID: 35876920
[TBL] [Abstract][Full Text] [Related]
18. De novo metastatic lobular breast carcinoma: A population-based study from SEER database.
Sun MS; Yan HC; Gao M; Liu HJ; Xu L
Asian J Surg; 2022 Dec; 45(12):2608-2617. PubMed ID: 35012851
[TBL] [Abstract][Full Text] [Related]
19. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial.
Falck AK; Fernö M; Bendahl PO; Rydén L
BMC Cancer; 2013 Nov; 13():558. PubMed ID: 24274821
[TBL] [Abstract][Full Text] [Related]
20. Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Kanjanapan Y; Lok SW; Gibbs P; De Boer R; Yeo B; Greenberg S; Barnett F; Knott L; Richardson G; Wong R; Nottage M; Collins IM; Torres J; Lombard J; Johns J; Harold M; Malik L
Breast Cancer Res Treat; 2020 Nov; 184(1):87-95. PubMed ID: 32779037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]